NEXYRA

Advanced Research

Unlocking Omics | Powering Precision

Multi-Omics Intelligence Powered by Nexyra

Your Partner
In AI- Driven Precision Medicine

NEXYRA
Advanced Research

Vision Statement

Our vision is to lead the future of precision biomedicine by setting a new standard in clinical and translational intelligence through AI-powered multi-omics and multimodal analytics integration. We convert complex omics and clinical data into actionable insights, accelerating the passage from the sample to interpretable and validated knowledge, with a direct impact on diagnosis, stratification and biomedical R+D decisions.

We envision a world where diseases are detected earlier, treatments are more precisely personalized, and prevention becomes proactive and data-driven, reliably connecting systems biology with actual clinical practice in highly complex areas (oncology, rare diseases, longevity, and other highly heterogeneous contexts).





Mission Statement

At Nexyra Advanced Research, our mission is to transform translational research and precision medicine through a data-driven, integrative, and multi-modal approach. We build solutions that combine AI, systems biology, and multi-omics analytics to integrate molecular and clinical data (genomics, transcriptomics, proteomics, metabolomics, and clinical variables, among others) and translate them into actionable biomedical intelligence.

Our goal is to raise the standard across four fronts:

1. patient stratification and precision diagnostics through robust biomarkers,
2. therapeutic target prioritization to support drug discovery and development,
3. predictive and prognostic modeling to enable truly personalized, measurable treatment strategies, and
4. accelerating data-driven R&D powered by multi-omics, by shortening the cycle from raw omics data to validated insights and decision-ready outputs.

We recognize that this impact cannot be achieved in isolation. That is why we work closely with clinical teams and hospitals, academic institutes, CROs, biotech companies, and pharmaceutical partners, providing a multi-omics intelligence layer that accelerates validation, reduces uncertainty, and improves decision-making in complex biomedical settings.



NEXYRA

Advanced Research

Scientific rigor & reproducibility

We commit to evidence that is robust, testable, and reproducible not just impressive. We document provenance and uncertainty so our outputs can be audited and trusted.

Clinical & translational impact

We optimize for decisions that change outcomes in real clinical and R&D settings. Every analysis must translate into actionability: stratify, predict, target, enroll, or treat.

Responsible AI & data stewardship

We treat patient and partner data as sensitive capital, protected by privacy-by-design and security-by-default. We build transparent, accountable models with explicit limitations, bias monitoring, and ethical use boundaries.

Integrative systems thinking

We integrate multi-omics and clinical modalities to understand biology as a system, not isolated signals. We balance statistical performance with mechanistic plausibility to guide validation and targetability.

CORE VALUES



Partnership & co-creation

We work as an embedded partner, co-defining hypotheses, endpoints, and success metrics with stakeholders. We operate with radical clarity on trade-offs, timelines, and deliverables no surprises.

Execution excellence: speed with discipline

We move fast while preserving scientific quality and operational reliability. We standardize what scales, automate what repeats, and prioritize relentlessly to deliver decisionready outputs**.**

Integrity & radical transparency

We earn trust by being honest about assumptions, uncertainty, and negative results. We never overpromise; we align expectations with what the data and methods can truly support**.**

Continuous learning & talent density

We invest in learning velocity benchmarks, reviews, and iteration are built into how we operate. We build high standards and continuously raise the bar in science, engineering, and delivery**.**

WHAT SETS NEXYRA APART?

ADVANCED AI SOLUTIONS

“At Nexyra Advanced Research, our expertise spans from robust classical machine learning to the latest advances in AI for biomedical data, including ensemble methods, non linear multivariate modeling, multi omics and multi modal fusion, deep learning architectures such as transformers, and LLM enabled scientific workflows for knowledge extraction and interpretation.

We take a solution first approach, selecting, tailoring, and validating methods based on the biology, the data reality, and the decision context of each project, whether biomarker discovery, target prioritization, predictive and prognostic modeling, or data driven R&D acceleration. Our commitment to trustworthy, reproducible, and explainable AI, supported by rigorous validation, uncertainty awareness, and transparent reporting, ensures reliable outputs that maximize partner confidence and real world impact.”



At Nexyra Advanced Research, we bring strong domain expertise in bioinformatics and the interpretation of complex multi omics data, including genomics, transcriptomics, exome based analyses, proteomics, and metabolomics. We specialize in extracting biological meaning from heterogeneous molecular and clinical signals, and in multi omics integration that connects these layers into a coherent, systems level view of disease biology.

This deep domain knowledge enables us to unlock comprehensive insights that drive precision diagnostics, biomarker strategies, and therapeutic discovery, supporting partners with decision ready outputs such as biomarker panels, target prioritization rationales, and predictive and prognostic models grounded in biological plausibility and rigorous validation.



PERSONALIZED CONSULTING APPROACH

At Nexyra Advanced Research, we deliver a personalized consulting approach that produces tailored solutions aligned with each partner's scientific question, data reality, and decision context. We begin by defining the biological hypothesis, the clinical objective or R&D goal, and the success criteria, then design an engagement plan that maximizes actionability, reduces uncertainty, and accelerates progress from data to decisions.

Through close collaboration with academic institutions, clinical organizations, and industry leaders, we co create a robust and innovative ecosystem that amplifies impact. By working iteratively and transparently with our partners, we translate complex multi omics evidence into decision ready outputs that support precision diagnostics, therapeutic discovery, and data driven R&D acceleration, ultimately speeding meaningful advancements in healthcare.



Services & Solutions



- **Multi omics analytics and multimodal AI solutions integrating molecular and clinical evidence into decision ready insights.**
- **Personalized diagnostics and precision medicine support, including patient stratification, biomarker panels, and predictive and prognostic modeling.**
- **Drug discovery enablement through therapeutic target prioritization and mechanistically grounded hypothesis generation.**
- **Drug repositioning and indication expansion support using integrated multi omics evidence and clinical context.**
- **Data driven R&D acceleration, shortening the path from complex omics datasets to validated, actionable conclusions.**
- **Predictive and prognostic model development based on integrated omics and clinical data for risk prediction, outcomes forecasting, and treatment response support**
- **Collaborative delivery model for biotech, pharma, hospitals, CROs, and academic partners**
- **Biomarker discovery.**

Multi-Omics Analytics and Multimodal AI Solutions

Multi Omics Analytics and Multimodal AI Solutions is Nexyra's core service for extracting actionable biomedical intelligence from complex molecular and clinical evidence. We integrate genomics, transcriptomics, exome based analyses, proteomics, and metabolomics together with relevant clinical variables and, when available, additional modalities such as imaging, to build a coherent systems level view of disease biology and patient heterogeneity.



The service is designed to answer decision critical questions in translational research and precision medicine, enabling biomarker strategies, therapeutic target prioritization, and the creation of predictive and prognostic models grounded in biological plausibility and rigorous validation. Our output is not raw analytics, but decision ready deliverables such as interpretable multi omics signatures, ranked hypotheses with mechanistic rationale, model performance and uncertainty summaries, and clear recommendations that partners can operationalize in R&D and clinical workflows.

AI-Driven Innovation at Nexyra Advanced Research

At Nexyra Advanced Research, we combine advanced AI with deep bioinformatics and systems biology expertise to accelerate precision medicine and data driven R&D. By integrating multi omics and multimodal evidence, including genomics, transcriptomics, exome based analyses, proteomics, metabolomics, and clinical data, and when available imaging and unstructured text, we build multimodal AI systems that translate complex biology into decision ready insights.

Our approach is designed to improve both predictive performance and real world robustness by unifying heterogeneous data layers into models that generalize across cohorts and reflect underlying disease mechanisms. The result is actionable outputs that partners can operationalize, from biomarker strategies and patient stratification to therapeutic target prioritization and predictive and prognostic models that support discovery and development programs.





Customized Methods for High Complexity Biology

At Nexyra Advanced Research, we take a solution driven approach, selecting and tailoring analytical and AI methods to the specific biology, data constraints, and decision objectives of each engagement. Rather than forcing a one size fits all pipeline, we adapt our multi omics and multimodal strategy to deliver the most reliable, actionable outcomes for precision medicine, therapeutic discovery, and data driven R&D acceleration.

We apply a full spectrum of advanced techniques, from rigorous statistical modeling and ensemble machine learning to state of the art deep learning approaches, including graph based methods, transfer learning, generative AI, transformers, and foundation model workflows adapted to biomedical data and multi omics integration.



We also prioritize explainable and trustworthy AI, ensuring that decision support outputs are transparent, interpretable, and aligned with partner needs, with clear uncertainty reporting and validation evidence. This combination of methodological breadth and practical rigor allows us to tackle complex biomedical challenges effectively, delivering solutions that are both innovative and operationally usable in real world R&D and clinical settings.



End-to-End, Scalable Solutions

At Nexyra Advanced Research, we deliver scalable, end to end solutions that support precision medicine, therapeutic discovery, and data driven R&D through high performance analytics and cloud ready execution. We translate complex multi omics and clinical evidence into decision ready outputs that partners can operationalize across programs and indications.

Rather than focusing on routine preprocessing, our value concentrates on the interpretation layer: multi omics integration, model development when needed, rigorous validation, and transparent reporting that connects results to real decisions. This ensures robust, reproducible outcomes across diverse biomedical applications, from biomarker strategies and patient stratification to target prioritization and predictive and prognostic modeling.





Omics Advances Powering Precision Medicine

Advances in omics technologies, from next generation sequencing to high resolution mass spectrometry, now enable comprehensive quantification of biomolecules across tissues, blood, and other biofluids. By capturing broad molecular signals across genomics, transcriptomics, exome based analyses, proteomics, and metabolomics, these platforms provide a systems level view of disease biology and patient heterogeneity.

At Nexyra Advanced Research, we leverage this breadth to translate complex omics and clinical evidence into actionable insights for precision medicine. This enables biomarker discovery for earlier detection, molecular subtyping, prognosis and risk prediction, and data informed treatment selection, supporting decision ready outputs for both clinical translation and R&D programs.

TYPES OF BIOMARKERS

we explore



Molecular Stratification Biomarkers
Functional subtypes (not limited to transcriptomics)

Predictive Response Biomarkers
For existing therapies (drug repurposing)

Multi-Omics Signatures of Active Mechanisms
Signaling pathways, metabolism, tumor microenvironment

Resistance and Escape Biomarkers
Particularly relevant in **GBM** and **PDAC**

The use of mechanism-based biomarkers reduces trial-and-error cycles, prevents the progression of weak hypotheses, and optimizes the use of preclinical and clinical resources and contributing to a more sustainable R&D model.



Addressing Challenges in Biomarker Translation

Data Complexity

Omics and clinical datasets are inherently high dimensional, noisy, and often sparse, which makes it difficult to extract sensitive and clinically meaningful biomarkers, especially when cohorts are limited or samples are heterogeneous.

At Nexyra Advanced Research, we apply AI and systems level multi omics integration to detect subtle phenotypic patterns within complex data. We build non linear predictive and prognostic models when appropriate, supported by rigorous validation design, careful feature stability assessment, and uncertainty aware reporting to maximize sensitivity, specificity, and real world generalizability.



Reproducibility and Translation Risk

Biomarker reproducibility is frequently undermined by weak validation practices, population heterogeneity, and technical variability such as batch effects, resulting in signals that fail to replicate across cohorts or settings.

We work with clinical and industry partners to enable unbiased validation across diverse cohorts and realistic settings. When cohort size is constrained, we leverage transfer learning and controlled use of public repositories and biobank resources to strengthen robustness, reduce data requirements, and improve replicability, while maintaining transparency on limitations and evidence strength.





Ensuring Prediction Interpretability

AI adoption in diagnostics and clinical decision support depends on trust, accountability, and regulatory readiness. At Nexyra Advanced Research, we design models and evidence packages that are transparent and traceable, so partners can understand what drives predictions and how reliable they are.

Our approach uses explainable AI methodologies to provide interpretable outputs, clear feature and pathway level drivers, and uncertainty aware reporting. We align interpretability with real clinical workflows and regulatory expectations, strengthening clinician confidence and supporting patient level communication when needed.

Innovating with Multimodal Diagnostics

We develop highly sensitive and specific biomarker strategies that integrate multiple molecular analytes across omics layers, combining genomics, transcriptomics, exome based analyses, proteomics, and metabolomics with relevant clinical context. By applying advanced AI and systems level integration, we generate multi analyte signatures tailored to patient heterogeneity, enabling more precise diagnostics, robust disease subtyping, and improved risk and outcome prediction for precision medicine programs.



Data Complexity

Multi omics and clinical datasets present structural challenges that limit classical biomarker development, including the curse of dimensionality where sample size is far smaller than the number of features, pervasive sparsity, and a low signal to noise ratio. These factors make true biological signals hard to distinguish from technical and cohort specific artifacts.

At Nexyra Advanced Research, we address this by applying AI and systems level multi omics integration to detect subtle molecular patterns within high complexity data. This enables robust biomarker and predictive models that can identify early and weak disease signals, including early stage tumour signatures when the phenotype is subtle and heterogeneous.



Prediction Interpretability

Interpretability is a prerequisite for real world adoption of AI in diagnostics and decision support. Without clear rationale and traceability, even strong performance fails to translate into clinical or R&D impact.
Nexyra designs explainable, transparent outputs to support five adoption drivers: clinician and partner trust and acceptance, accountability of decisions, regulatory readiness, patient understanding where applicable, and safer deployment through uncertainty awareness and documented limitations.



Lack of Reproducibility

One of the biggest barriers to translating biomarkers into real world personalized oncology is lack of reproducibility. Signals often fail to replicate due to inconsistent sample handling and processing, weak validation practices, and real population heterogeneity amplified by batch effects and multi center variability.

At Nexyra Advanced Research, we address this by emphasizing robustness and external validity, prioritizing biomarkers that remain stable across cohorts and conditions. Conceptually, we move beyond static biomarker panels toward molecular fingerprints, multi feature signatures that capture disease biology more faithfully and support stronger generalization in heterogeneous settings.

Multimodal Diagnostics

We support multimodal diagnostic strategies by integrating multi analyte evidence and multi omics profiles into coherent, decision ready signatures. When available, this includes blood based molecular sources such as platelet derived RNA signals, extracellular vesicle cargo such as lipids, proteins, and RNAs, and circulating cell free DNA mutation profiles, combined with broader multi omics layers.

By integrating proteomics, lipidomics, transcriptomics, and genomics with clinical context, we generate molecular fingerprints that enable more sensitive and specific detection, improved disease subtyping, and more reliable risk and outcome prediction for precision medicine and R&D programs.

Drug Repurposing and Discovery Solutions



Developing a new drug typically takes 10 to 15 years, with capitalized R&D costs commonly estimated above $2.5B per approved asset, and only around ~10 to 12 percent of programs entering clinical testing ultimately reaching approval, which makes early prioritization and de risking decisive. AI is increasingly central to improving this equation, with BCG estimating 25 to 50 percent time and cost savings in discovery to preclinical when applied effectively. web-assets.

Nexyra addresses the “invisible bottleneck” in repurposing and discovery by moving beyond single omics correlations and building mechanism grounded, multi omics and clinical evidence to prioritize disease target drug axes, reduce biological risk, and enable earlier go or no go decisions.

What Nexyra delivers

- Ranked repurposing candidates and discovery hypotheses supported by integrated genomics, transcriptomics, exome based analyses, proteomics, metabolomics, and clinical context
- Mechanistic rationale and network coherence evidence to improve explainability and translational confidence
- Decision ready outputs for portfolio selection and validation planning, designed to accelerate R&D execution and reduce late stage attrition



Drug development typically requires 12–15 years and ≈ US$2B of cumulative investment, with extreme attrition across stages: fewer than 1 in 10,000 initial candidates ultimately reach regulatory approval.

The Promise of Drug Repurposing

Drug repurposing, identifying new indications for approved drugs or previously shelved candidates, offers a high leverage path to accelerate therapeutic innovation by reusing existing pharmacology and safety knowledge. Established clinical experience can shorten early development work and de risk parts of the safety package, enabling faster program decisions and earlier patient access.

Why it matters

- Faster development: known safety and formulation history can compress early stage timelines and focus effort on efficacy and positioning.
- Higher probability of success in many cases: reviews and industry analyses often cite approval rates around ~30% for repurposed assets versus ~10% for de novo development, while also noting variability by indication and that efficacy remains the main limiter.
- More cost effective: repositioning can reduce time, cost, and biological risk compared with starting from scratch.
- With the growth of high throughput omics and expanding public and proprietary biomedical datasets, computational drug repurposing has become a systematic way to identify candidates at scale, moving from anecdotal serendipity to evidence based prioritization.

Nexyra angle

Nexyra strengthens repurposing by prioritizing candidates through multi omics and clinical mechanistic rationale, not isolated correlations, enabling early go or no go decisions supported by traceable disease target drug axes and context specific evidence.



Our Approach: AI Powered Drug Discovery and Repurposing

At Nexyra Advanced Research, we use advanced AI and systems biology to convert multi omics and clinical evidence into decision ready discovery and repurposing hypotheses. Our integrative models unify heterogeneous biomedical data to reduce biological risk, accelerate early prioritization, and improve the quality of go or no go decisions across the R&D pipeline.

Data sources we leverage

- Drug chemical structures and bioactivity profiles
- Drug targets, mechanisms of action, and disease associations
- Molecular perturbation evidence and pathway level signals derived from multi omics data
- Protein protein interaction networks and functional interaction maps
- Gene disease resources, GWAS signals, and variant to phenotype associations
- Real world molecular context from genomics, transcriptomics, exome based analyses, proteomics, and metabolomics, linked to clinical phenotypes
- Drug safety signals including side effects, toxicity profiles, and drug drug adverse interactions
- Clinical trial evidence and outcomes when available
- Combination and synergy evidence from high throughput screening when provided by partners or accessible through curated sources

Key capabilities

- Target identification and prioritization by mechanistic coherence across omics layers and disease context
- Repurposing and indication expansion by matching molecular fingerprints to drug mechanism and clinical phenotype
- Toxicity and safety risk assessment support through integrated safety signals and biological plausibility checks
- Drug synergy and interaction analysis to identify promising combinations and flag adverse interaction risk
- Clinical translation support by strengthening hypothesis plausibility, cohort context fit, and evidence packaging to improve trial strategy and success probability

By combining AI's predictive power with mechanistically grounded, multi source biological evidence, Nexyra accelerates discovery and repurposing while improving robustness, traceability, and partner confidence in the decisions that matter.

NEXYRA
Advanced Research



Personalized Consulting Approach

Mechanism first, not correlation first
We prioritize disease target drug hypotheses grounded in multi omics mechanistic rationale, reducing biological risk and avoiding false prioritizations.

Multi omics and multimodal integration built for complexity
We connect genomics, transcriptomics, exome based analyses, proteomics, metabolomics, and clinical context into a unified systems level view that captures heterogeneity.

Decision ready deliverables, not exploratory analytics
We deliver ranked candidates, biomarker strategies, target prioritization rationales, and predictive and prognostic models that partners can operationalize in R&D and clinical workflows.

Trustworthy and explainable AI
Our outputs are transparent and traceable, with clear validation evidence and uncertainty awareness to support confidence, accountability, and regulatory readiness.

R&D acceleration with measurable impact
We shorten the cycle from complex data to actionable decisions, enabling earlier go or no go calls, faster validation planning, and more efficient portfolio execution.

Partner embedded execution
We work closely with biopharma, hospitals, CROs, and academic teams, aligning on success metrics upfront and iterating fast with disciplined scientific rigor.

Innovative Expertise

At Nexyra Advanced Research, we build high trust, collaborative partnerships tailored to each client's scientific question, data reality, and decision context. Our consulting model is designed to deliver measurable outcomes through:

AI Excellence
Expertise across ensemble machine learning, graph based methods, generative AI, transformers, and foundation model workflows, with a strong focus on explainable and trustworthy AI for real world biomedical applications.

Solution Driven Execution
We prioritize fit for purpose solutions over rigid methodologies, selecting, adapting, or innovating approaches to match each project's objectives, constraints, and success criteria.

Multi Omics and Multimodal Integration
Integrated interpretation of genomics, transcriptomics, exome based analyses, proteomics, metabolomics, and other omics layers, combined with clinical variables and, when available, imaging and unstructured text to generate holistic, systems level insights.

Decision Ready Delivery
We focus on the interpretation and decision layer, producing outputs partners can operationalize, including biomarker strategies, therapeutic target prioritization rationales, and predictive and prognostic models supported by rigorous validation.

Scalable Deployment
Cloud ready and high performance execution when required, enabling efficient delivery across projects of different sizes while maintaining reproducibility, traceability, and governance.

Trusted Excellence

At Nexyra Advanced Research, our credibility in AI driven precision medicine is anchored in excellence, scientific rigor, and integrity:

Award Recognized Team
Our work has been acknowledged through awards and recognitions, including EIT Health, Parque Científico distinctions, and W Startup Community awards, reflecting our ability to execute innovation with real world relevance.

Ethical and Transparent Practices
We prioritize responsible and explainable AI, applying high standards of quality, accountability, data stewardship, and traceability to support trust and regulatory readiness.

Proven Impact
We focus on measurable outcomes that advance precision diagnostics, biomarker strategies, therapeutic discovery, and data driven R&D acceleration, consistently translating complex evidence into decision ready deliverables.

Sustainable Development Goals

Nexyra Advanced Research contributes to the SDGs through AI-powered multi-omics and clinical intelligence to accelerate diagnosis, stratification, therapeutic discovery, and biomedical R&D decisions.

SDG 3 · Good Health and Well-being
We accelerate early detection, patient stratification, and predictive/prognostic models based on omics and clinical data, supporting precision medicine and improved outcomes in complex diseases. We reject projects that go against patients' health and autonomy.

SDG 9 · Industry, Innovation, and Infrastructure
We develop deeptech capabilities (biomedical AI, systems biology, multi-omics integration) and strengthen innovation infrastructures for translational R&D with reproducible, decision-ready deliverables.

SDG 10 · Reduced Inequalities
We promote approaches that improve the generalizability of biomarkers and models across heterogeneous cohorts, making precision medicine more robust and applicable to diverse populations. In addition, we have a social support program for people with limited economic resources, enabling them to access healthy foods that can contribute to better health.

SDG 12 · Responsible Consumption and Production
We increase R&D efficiency by reducing low-value iterations, prioritizing hypotheses and candidates with multi-omics and clinical evidence, and decreasing the cost and experimental waste associated with delayed decisions.

SDG 17 · Partnerships for the Goals
We work with hospitals, clinical teams, institutes, CROs, biotech, and pharma companies to co-create evidence and accelerate validation, enabling a collaborative ecosystem with measurable impact.

SDG 16 · Peace, Justice, and Strong Institutions
We strengthen data governance and trust through responsible AI practices, traceability, transparency, and interpretability to support accountability and regulatory readiness.

Contact Nexyra

Your AI driven multi omics journey starts here.

Get in touch to schedule a consultation and explore how Nexyra's AI powered, multi omics and multimodal solutions can accelerate biomarker discovery, predictive and prognostic modeling, therapeutic target prioritization, and data driven R&D decisions.



Partners:

Cluster de Inteligencia Artificial

Clusters Madrid

fundación para el conocimiento madrid

FUNDACIÓN Parque Científico de Madrid

Plataforma Biotech
Spanish Biotech Platform

f SéNeCa (+)
Agencia de Ciencia y Tecnología Región de Murcia

UCAM UNIVERSIDAD

APTenisa

EU-LAC
Digital Accelerator

enterprise europe network

DISRUPTIVE
Plataforma Tecnológica Española de Tecnologías Disruptivas

EP PerMed
European Partnership for Personalised Medicine

TEF-Health
Testing and Experimentation Facility for Health AI and Robotics

SCAN AND LEARN MORE

Visit our website and X and LinkedIn profile

CONTACT

connect@nexyraresearch.com

Parque Científico de Madrid. C. Faraday, 7,
Fuencarral-El Pardo, 28049 Madrid

www.nexyraresearch.com

BOOK A MEETING

NEXYRA

Advanced Research

Unlocking Omics | Powering precision

NEXYRA
Advanced Research

Unlocking Omics | Powering precision